Floatz logo

Alpha-Interferon

Unspecified Childhood Solid Tumor, Protocol Specific

Children's Oncology GroupPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Unspecified Childhood Solid Tumor, Protocol Specific cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
City of Hope Medical Center
Phase 2/3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2/3BBB
FILGRASTIM
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Carboplatin
Seoul National University Hospital
Phase 2/3BBB
Thiotepa
Roswell Park Cancer Institute
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Alpha-Interferon is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal cell carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
kidney cancerDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →